Category: PMCPA Case of the Week

Cases selected for the AskAnzal weekly PMCPA insight newsletter

8 Mar 2026

AUTH/3239/8/19: Pharmacist v Colonis Pharma Limited – promotion of Melatonin Oral Solution and off-label implication

A pharmacist complained a launch letter promoted off-label use of Melatonin 1mg/ml Oral Solution. The Panel ruled the…

8 Mar 2026

AUTH/2115/4/08 Roche v GlaxoSmithKline: Press releases for Tykerb/Tyverb (lapatinib) on corporate website

Roche challenged two GSK corporate press releases about lapatinib (Tykerb/Tyverb). The Panel found one release misleading on adverse…

8 Mar 2026

Allergan v Merz Pharma (AUTH/2270/10/09): β€œAt least as effective as Botox” claim from non-inferiority studies ruled misleading

Merz promoted Xeomin as β€œAt least as effective as Botox with a similar safety profile” on an exhibition…

8 Mar 2026

AUTH/2311/4/10: Anonymous v AstraZeneca – Seroquel meeting alleged off-label promotion (No breach)

Anonymous alleged an AstraZeneca meeting misled attendees and promoted Seroquel for borderline personality disorder. Panel found no evidence…

8 Mar 2026

AUTH/3164/2/19: Anonymous v Merck Sharp & Dohme (A/B tested emails to MSD Connect) – No breach

Two near-identical MSD Connect emails with different subject lines were sent within seconds due to a third-party technical…

8 Mar 2026

AUTH/2391/2/11: Takeda v AstraZeneca – Zoladex price reduction letter and β€œNo other LHRHa…” survival claim (No breach)

Takeda challenged AstraZeneca’s β€œNo other LHRHa has demonstrated survival benefits in all 3 stages…” claim in a Zoladex…

8 Mar 2026

AUTH/3075/9/18: Director v Lundbeck β€” Clinical trial disclosure (outwith scope; no breach)

PMCPA case AUTH/3075/9/18 (Director v Lundbeck) concerned clinical trial disclosure but was ruled outwith the scope of the…

8 Mar 2026

AUTH/2525/7/12: Clinical Lead Pharmacist v ProStrakan (Abstral) – post-operative use discussion (No breach)

A hospital pharmacist alleged ProStrakan reps discussed Abstral for post-operative urology patients (off-label). Panel found the complaint not…

8 Mar 2026

AUTH/2611/6/13: Anonymous renal nurse v Janssen (Durogesic branded pens in conference delegate bags) – No breach on appeal

A renal nurse complained that Durogesic DTrans branded pens were in BRS 2013 delegate bags. Panel found a…

8 Mar 2026

AUTH/2758/5/15: Galen v Stirling Anglian β€” CosmoCol abbreviated ad and leavepiece breaches (pack/cost info and missing active ingredients)

MIMS β€œabbreviated” CosmoCol ad included pack size/cost and other claims, so needed prescribing info. Both the ad and…

⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week β€” free.

Subscribe Free
🎓 AQP Training